E0 ConsensusPreliminaryPEM not requiredReview-NarrativePeer-reviewedReviewed
Standard · 3 min
Fecal microbiota transplantation: past, present and future.
Aroniadis, Olga C, Brandt, Lawrence J · Current opinion in gastroenterology · 2013 · DOI
Quick Summary
This review examines fecal microbiota transplantation (FMT), a treatment that restores healthy gut bacteria by transferring stool from a healthy donor to a patient. While FMT works very well for a specific bacterial infection, researchers are exploring whether it might help with other conditions including gut disorders and diseases affecting other parts of the body, such as chronic fatigue syndrome. The authors emphasize that more research is needed before FMT can be widely used for conditions beyond its proven application.
Why It Matters
This review is significant for ME/CFS because it explicitly identifies chronic fatigue syndrome as a condition potentially linked to dysbiosis and amenable to microbiota-based interventions. Understanding the role of gut microbiota dysfunction in ME/CFS pathogenesis could open new treatment avenues and provides a framework for why some ME/CFS patients report GI symptoms. The recognition that intestinal microbiota influences cellular immunity and energy metabolism directly relates to core ME/CFS pathophysiology.
Observed Findings
Fecal microbiota transplantation is highly effective as a cure for recurrent Clostridium difficile infection (RCDI)
An imbalanced intestinal microbiota (dysbiosis) is associated with CDI, IBD, IBS, and chronic constipation
The intestinal microbiota plays important roles in cellular immunity and energy metabolism
Dysbiosis has been implicated in non-gastrointestinal autoimmune diseases, chronic fatigue syndrome, obesity, and some neuropsychiatric disorders
FMT has been attempted in treatment of various gastrointestinal and non-gastrointestinal diseases beyond RCDI
Inferred Conclusions
The complex role of intestinal microbiota in maintaining health extends beyond gastrointestinal function to immune regulation and cellular energy production
FMT's success in RCDI suggests potential therapeutic value in dysbiosis-related conditions, but this application requires controlled clinical trials
Increased understanding of microbiota function in health and disease is necessary before widespread clinical application of FMT outside RCDI treatment can be justified
Remaining Questions
Which specific microbial species or bacterial communities are most important for preventing or treating chronic fatigue syndrome?
What This Study Does Not Prove
This review does not establish that FMT is an effective or safe treatment for ME/CFS, only that dysbiosis has been implicated in its pathogenesis and that further research is warranted. The paper does not prove causation between microbiota imbalance and chronic fatigue syndrome—only that an association has been observed and deserves investigation. Being a 2013 review, it does not include more recent controlled trials of FMT in ME/CFS or related conditions.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.